-
Product Insights
NewAlpha Thalassaemia – Drugs In Development, 2024
Empower your strategies with our Alpha Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions. Alpha thalassaemia (or α-thalassaemia) is a group of inherited blood disorders, characterised by a reduced production of the α-globin chains of the haemoglobin molecule, while the β-globin chains are normally produced. This means that there will be an accumulation of the β-(unpaired) globin chains, within the developing red cell. The production of the α-globin chains is regulated by four α-genes, two on...
-
Product Insights
NewEosinophilia – Drugs In Development, 2024
Empower your strategies with our Eosinophilia – Drugs In Development, 2024 report and make more profitable business decisions. Eosinophilia is defined as an increase of circulating eosinophils. The count of eosinophilis may rise when there is an allergy, has certain infections, especially with parasites, or some types of leukemia. The Eosinophilia drugs in development market research report provide comprehensive information on the therapeutics under development for Eosinophilia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route...
-
Product Insights
NewHypereosinophilic Syndrome – Drugs In Development, 2024
Empower your strategies with our Hypereosinophilic Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical...
-
Product Insights
NewLymphedema – Drugs In Development, 2024
Empower your strategies with our Lymphedema – Drugs In Development, 2024 report and make more profitable business decisions. Lymphedema is an abnormal buildup of lymph fluid (protein-rich fluid) in the soft body tissues due to a damaged or blocked lymphatic system. It can be a primary lymphedema (born with lymphedema) or a secondary lymphedema (damage to the lymphatic system due any surgery, cancer, cancer treatment, infection, etc). Possible signs include swelling of the arms or legs. The Lymphedema drugs in development...
-
Product Insights
NewThrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Drugs In Development, 2024
Empower your strategies with our Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, rapid heart rate, shortness of breath, speech changes, weakness, and yellowish color to the skin (jaundice). Treatment includes surgery to remove...
-
Product Insights
NewFibrinogen Deficiency (Factor I Deficiency) – Drugs In Development, 2024
Empower your strategies with our Fibrinogen Deficiency (Factor I Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Fibrinogen deficiency (Factor I deficiency), is a rare inherited bleeding condition due to bi-allelic mutations in one of the three fibrinogen genes FGA, FGB and FGG; these encode α, β and γ fibrinogen polypeptides, respectively, which are folded together to form the mature fibrinogen hexameric structure. Mutations in the fibrinogen genes either affect the quantity of circulating fibrinogen (as...
-
Product Insights
NewHemoglobinopathies – Drugs In Development, 2024
Empower your strategies with our Hemoglobinopathies – Drugs In Development, 2024 report and make more profitable business decisions. Hemoglobinopathy is a group of disorders in which there is abnormal production or structure of the hemoglobin molecule. It is passed down through families (inherited). This group of disorders includes hemoglobin C disease, hemoglobin S-C disease, sickle cell anemia, and thalassemias. Some hemoglobinopathies result in anemias that are severe in patients who are homozygous but mild in those who are heterozygous. Some patients...
-
Product Insights
NewSickle Cell Disease With Vaso-Occlusive Crisis – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease With Vaso-Occlusive Crisis – Drugs In Development, 2024 report and make more profitable business decisions. Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration, and infection. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, blood transfusion, and surgery. The Sickle Cell Disease With Vaso-Occlusive Crisis drugs in development market...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...
-
Product Insights
NewAnemia of Chronic Disease – Drugs In Development, 2024
Empower your strategies with our Anemia of Chronic Disease – Drugs In Development, 2024 report and make more profitable business decisions. Anemia of chronic disease (ACD) or anemia of inflammation is a type of anemia that affects people who have conditions that cause inflammation, such as infections, cancer, autoimmune diseases, and chronic kidney disease (CKD). In ACD there is reduced iron levels in the blood. Symptoms includes fast heartbeat, body aches, fainting or feeling dizzy or light-headed, feeling tired or weak,...